← Human Trials & Peer-Reviewed Studies
Examining the Feasibility of Prolonged Beta-Hydroxybutyrate-Containing Supplement Drink Consumption in Adults with Type 2 Diabetes: A Randomized Controlled Pilot Trial.
Plain-language guide to PMID 40525864 (2025): double-blind randomized controlled trial of Copper (Supplement).
Key Facts
- PMID
- 40525864
- Journal
- Journal of the American Nutrition Association
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Marcotte-Chénard A et al. (9 authors)
- DOI
- 10.1080/27697061.2025.2518116
- Registered trial
- NCT05477368
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Copper (Supplement), published as a randomized controlled trial.
To conduct a double-blind, remote, randomized, placebo-controlled pilot trial to determine the feasibility of repeated and prolonged beta-hydroxybutyrate (BHB)-containing supplement ingestion in free-living adults with type 2 diabetes (T2D).
Who Took Part
PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.
Feasibility was defined based on a priori specified criteria using recruitment rate, drop-out rate, compliance, gastrointestinal (GI) symptomatology, and data availability.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and pilot.
The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.
Some participants received a placebo instead of Copper (Supplement), giving a reference point.
It is described as a pilot, a small early test of whether a larger Copper (Supplement) study would be practical.
What Was Measured
The subject headings attached to it are Pilot Projects, Diabetes Mellitus, Type 2, 3-Hydroxybutyric Acid, Dietary Supplements, Feasibility Studies and Butylene Glycols.
The authors tagged it with the keywords Exogenous ketones, continuous glucose monitor, gastrointestinal, glucose control and ketosis.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).
The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2025 (Journal of the American Nutrition Association), a journal based in United States.
More context: the Copper (Supplement) compound page, all human trials.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.